|For more information and other transactions visit www.XDATA.com|
|XDATA – November 6th 2015|
|Fractyl Laboratories issued equity for a total of $37.17 million in a non-brokered investment round. The transaction which started on October 23rd, garnered the support of sixteen investors. Two previous unregistered financing rounds raised an estimated $62.98 million.|
|Fractyl Laboratories develops a minimally invasive, device-based, implant-free duodenal mucosal resurfacing procedure (Revita DMR) that directly addresses the intestinal hormonal impairment that contributes to insulin resistance and changes how the body absorbs and processes sugar. The company is backed by Mithril Capital Management, General Catalyst, Bessemer Venture Partners, and Domain Associates.|
|The company, led by Harith Rajagopalan, is headquartered in Waltham MA. Fractyl Laboratories elected to keep its revenues undisclosed.
The executive team includes Jay Caplan and Lisa Davidson.
The board of directors includes Ajay Royan, Allan Will, Christopher Gabrieli, Nimesh Shah and Stanley Lapidus.
The company has raised an estimated total of $100.15 million via private unregistered security offerings.
Company: Fractyl Laboratories
Industry: Other Health Care
Amount offered: $37.17 million
Amount placed: $37.17 million
SEC filing: Source
First sale: 10-23-2015
Data as of: 11-06-2015
Telcare placed 95% of its non-brokered mezzanine financing with seven backers. The company launched the offering to raise $36.71 million, so far investors started to subscribe to $34.71 million on October 3rd. The company closed four previous unregistered private placements which raised an estimated $50.04 million.
The company is headquartered in Bethesda MD. Telcare kept its revenues undisclosed.
The executive team includes Andrew Flanagan, John R Dwyer and Jonathan C Javitt.
The board of directors includes Casper De Clercq, Kenneth Melani, Patrick Flynn and Scott Carter.
The company has raised an estimated total of $84.75 million via private unregistered security offerings.
Status: First close
Industry: Other Health Care
Amount offered: $36.71 million
Amount placed: $34.71 million
First sale: 10-03-2014
Data as of: 10-20-2014
Flexible Medical Systems LLC, does business as FlexMed, sold $301,785 worth of equity securities to eleven investors, completing 45% of its expected offering size. The offer was placed directly without the services of a placement agent. The company raised an estimated $7.5 million since it foundation in September 2005.
FlexMed is commercializing a proprietary microchip technology which provides access to interstitial fluid (ISF) without using a needle and drawing blood. The outermost layer of the epidermis (stratum corneum) consists of layers of corneocytes with continuous lipid bilayers that effectively contain fluid inside the body. The underlying principle that keeps body fluid in (and external fluids out) is repulsion of aqueous fluid by the lipids in the same way as oil repels water. Flexmed’s proprietary microchip technology temporarily disrupts the continuity of the lipid bilayer with tiny electrical signals, rather like shaking oil and water, allowing fluids to flow through the open channel created across the stratum corneum.
The company currently focuses on developing transdermal sensing products for glucose monitoring related to diabetes. The company plans to pursue other applications such as transdermal drug delivery in the future.
FlexMed is headquartered in Rockville, MD. and is lead by Joseph A. Marcanio.